A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes
- 17 September 1998
- journal article
- Published by Elsevier BV in Brain Research
- Vol. 805 (1-2), 259-262
- https://doi.org/10.1016/s0006-8993(98)00710-0
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- 6-[18F]Fluoro-l-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primatesBrain Research, 1997
- Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys.Experimental Neurology, 1996
- Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusionBrain Research, 1995
- Dopamine Terminal Loss and Onset of Motor Symptoms in MPTP-Treated Monkeys: A Positron Emission Tomography Study with 11C-CFTExperimental Neurology, 1994
- The ECAT EXACT HRJournal of Computer Assisted Tomography, 1994
- 6-[18F]Fluoro-l-DOPA metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomographyBrain Research, 1991
- Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSFBrain Research, 1987
- Hemiparkinsonism in monkeys after unilateral internal carotid artery artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)Life Sciences, 1986